The market disagrees. Animal studies mean little at this point and investors are well aware of leronlimab’s use in monotherapy. What we don’t have is a phase 3 study with statically significant results showing efficacy in mono therapy patients. Until we do, animal studies and 5 patient cohorts mean little.